Journal
PATHOLOGY
Volume 44, Issue 6, Pages 552-556Publisher
ELSEVIER
DOI: 10.1097/PAT.0b013e3283583f5d
Keywords
CD20 antigen; immunohistochemistry; myeloma
Categories
Funding
- HSANZ/Novartis scholarship
- HOTT fellowship
Ask authors/readers for more resources
Aims: A number of clinicopathological features have been attributed to the CD20 positive subset of plasma cell myeloma (PCM). CD20 is an appealing therapeutic target given the success with monoclonal antibody regimens in a spectrum of B cell lymphomas. To date, a small number of reports have described CD20(+) PCM as a unique subset, and these are not conclusive, especially taking into consideration reporting bias. This study aims to further identify the clinicopathological features of CD20(+) PCM. Methods: A retrospective analysis of all newly diagnosed PCM between 2003 and 2010 was undertaken. Trephine material was retrieved and reviewed for CD20, and for positive cases an extended immunohistochemical (IHC) panel including cyclin D1 was subsequently performed. Results: The review of our 40 cases and those described in the literature demonstrated that these are heterogeneous with regard to clinical features, morphology, biochemical features, immunophenotype, and cytogenetics. Conclusion: Based on our study and review of the literature, CD20(+) PCM cases represent a heterogeneous disease and not a unique clinicopathological entity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available